ROCA Blood Test Class Action Lawsuit Investigation

Investigating a class action lawsuit on behalf of individuals who purchased the Risk of Ovarian Cancer Algorithm (ROCA) blood test.  The ROCA blood test is marketed to detect the likelihood of a woman having ovarian cancer. Abcodia, the manufacturer of the test, claims it detects twice the number of cancers than the CA-125 test.  The FDA, however, recently recommended against using currently offered tests to screen for ovarian cancer.  The FDA stated that "there are currently no screening tests for ovarian cancer that are sensitive enough to reliably screen for ovarian cancer without a high number of inaccurate results."  The FDA specifically noted that current available data does not support the ROCA marketing claims.  If you purchased a ROCA test, please contact us.

Disclaimer